ICU Medical (NASDAQ:ICUI) Given New $182.00 Price Target at KeyCorp

ICU Medical (NASDAQ:ICUI) had its price target increased by equities researchers at KeyCorp from $164.00 to $182.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical instruments supplier’s stock. KeyCorp’s target price indicates a potential upside of 15.67% from the stock’s current price.

ICUI has been the subject of a number of other research reports. BTIG Research initiated coverage on shares of ICU Medical in a report on Monday, June 15th. They issued a “buy” rating and a $170.00 price objective for the company. Needham & Company LLC upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research report on Wednesday, May 27th. Zacks Research raised shares of ICU Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Piper Sandler lowered their price objective on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Finally, Sanford C. Bernstein lowered shares of ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Three research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $172.00.

ICU Medical Trading Down 0.1%

NASDAQ:ICUI opened at $157.34 on Tuesday. The company has a market cap of $3.93 billion, a PE ratio of 85.05, a P/E/G ratio of 2.20 and a beta of 0.76. The business’s 50 day moving average is $141.41 and its two-hundred day moving average is $139.29. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. ICU Medical has a 52 week low of $107.00 and a 52 week high of $162.85.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, beating analysts’ consensus estimates of $1.78 by $0.19. The business had revenue of $525.77 million during the quarter, compared to the consensus estimate of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business’s quarterly revenue was down 12.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, analysts predict that ICU Medical will post 6.51 EPS for the current year.

Insiders Place Their Bets

In related news, Director David C. Greenberg sold 2,424 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the transaction, the director directly owned 7,960 shares in the company, valued at $978,363.60. This represents a 23.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the sale, the vice president owned 19,460 shares in the company, valued at $2,414,596.80. The trade was a 11.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On ICU Medical

A number of hedge funds have recently made changes to their positions in the business. Hilton Head Capital Partners LLC acquired a new stake in ICU Medical in the 4th quarter valued at approximately $32,000. Covestor Ltd lifted its holdings in ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 126 shares during the period. Strs Ohio increased its stake in ICU Medical by 60.0% during the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after buying an additional 300 shares during the period. Rockefeller Capital Management L.P. raised its position in shares of ICU Medical by 21.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 146 shares in the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in shares of ICU Medical in the fourth quarter valued at approximately $120,000. Institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.